Orexigen Therapeutics Newswire

Orexigen Therapeutics Newswire

Comprehensive Real-Time News Feed for Orexigen Therapeutics.

Results 1 - 20 of 48 in Orexigen Therapeutics

  1. Contrasting Tetraphase PharmaceuticalsRead the original story w/Photo

    Saturday Sep 22 | Daily Political

    Tetraphase Pharmaceuticals and Orexigen Therapeutics are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership. Orexigen Therapeutics has higher revenue and earnings than Tetraphase Pharmaceuticals.

    Comment?

  2. Contrasting Tetraphase PharmaceuticalsRead the original story w/Photo

    Monday Sep 17 | AmericanBankingNews.com

    Tetraphase Pharmaceuticals and Orexigen Therapeutics are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. 40.9% of Tetraphase Pharmaceuticals shares are held by institutional investors.

    Comment?

  3. Ninth Circuit Addresses Use of Doctrines of Judicial Notice and...Read the original story w/Photo

    Sep 6, 2018 | jdsupra.com

    ... The application of these tools was recently addressed in a published Ninth Circuit opinion, Khoja v. Orexigen Therapeutics , Case No. 16-56069 (9th Cir. 2018), in which the panel noted a "concerning pattern in securities cases" in which "overuse" of ...

    Comment?

  4. 9th Circ. Makes Motions to Dismiss More Difficult in Securities LitigationRead the original story w/Photo

    Sep 4, 2018 | Law.com

    On Aug. 13, a panel of the U.S. Court of Appeals for the Ninth Circuit issued an opinion in a securities fraud class action, Khoja v. Orexigen Therapeutics, which could dampen a defendant's use of judicial notice and incorporation-by-reference to aid in its motion to dismiss, especially in the securities class action setting.

    Comment?

  5. Orexigen Therapeutics (OREX) Price Target Lowered to $0.02 at S&P Equity ResearchRead the original story w/Photo

    Aug 19, 2018 | The Breeze

    ... The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75. Orexigen Therapeutics has a 52 week low of $0.17 and a 52 week high of $3.81. The stock has a market capitalization of $4.21 million, a P/E ratio of ...

    Comment?

  6. The Ninth Circuit Tries to Rein in Extraneous Documents in Securities Motions to DismissRead the original story w/Photo

    Aug 18, 2018 | Business Law Prof Blog

    ... motion to dismiss is really a mini motion for summary judgment. This week, in a case called K hoja v. Orexigen Therapeutics , No. 16-56069 , the Ninth Circuit tried to draw a line in the sand, but as far as I'm concerned, did not go nearly far ...

    Comment?

  7. Orexigen Therapeutics (OREX) Given New $0.02 Price Target at S&P Equity ResearchRead the original story w/Photo

    Aug 15, 2018 | AmericanBankingNews.com

    S&P Equity Research's target price points to a potential downside of 91.03% from the company's current price. Shares of Orexigen Therapeutics stock traded down $0.12 during trading on Wednesday, reaching $0.22.

    Comment?

  8. Pernix Wins Auction; Orexigen's Sale Of Contrave Looks To Be CompleteRead the original story w/Photo

    Jun 27, 2018 | Seeking Alpha

    Orexigen Therapeutics will soon be no more. After filing for bankruptcy and placing itself on the auction block, a sole bidder, Nalproprion Pharmaceuticals, has been declared the winner and will acquire essentially all assets and some limited liabilities for a sum of $75 million.

    Comment?

  9. Somewhat Positive Press Coverage Somewhat Unlikely to Impact Orexigen Therapeutics (OREX) Share PriceRead the original story w/Photo

    Jun 8, 2018 | Daily Political

    Press coverage about Orexigen Therapeutics has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  10. Somewhat Positive Media Coverage Somewhat Unlikely to Affect Orexigen Therapeutics (OREX) Stock PriceRead the original story w/Photo

    May 29, 2018 | Daily Political

    News headlines about Orexigen Therapeutics have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time.

    Comment?

  11. Orexigen Therapeutics (OREX) Earns News Impact Score of 0.04Read the original story w/Photo

    May 19, 2018 | IntersportsWire

    News coverage about Orexigen Therapeutics has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  12. Orexigen Therapeutics (OREX) Given Daily Coverage Optimism Score of 0.04Read the original story w/Photo

    May 14, 2018 | IntersportsWire

    News stories about Orexigen Therapeutics have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time.

    Comment?

  13. Anti-Obesity Prescription Drugs Market: Global Industry Analysis,...Read the original story

    May 10, 2018 | Emailwire.com

    ... and market share for each manufacturer, covering o F Hoffmann La Roche o Arena Pharmaceuticals o Orexigen Therapeutics o Phentermine and Topiramate o VIVUS, Inc o Liraglutide o Bupropion and Naltrexone o Orlistat o Bupropion and Naltrexone o Novo ...

    Comment?

  14. Orexigen Therapeutics (OREX) Given Daily News Impact Rating of 0.00Read the original story w/Photo

    May 9, 2018 | Daily Political

    News coverage about Orexigen Therapeutics has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time.

    Comment?

  15. Orexigen Therapeutics (OREX) Receiving Somewhat Positive Media Coverage, Study ShowsRead the original story w/Photo

    Apr 29, 2018 | IntersportsWire

    News coverage about Orexigen Therapeutics has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources.

    Comment?

  16. Seth Klarman Dives Into Orexigen in Wake of SaleRead the original story w/Photo

    Apr 27, 2018 | GuruFocus.com

    Baupost Group's Seth Klarman disclosed this week he plunged into floundering pharmaceutical company Orexigen Therapeutics Inc. on April 13, buying over 7 million shares. Klarman, whose investments range from traditional value plays to distressed debt and liquidations, boosted his stake in the San Diego-based company, which focuses on weight loss and obesity, for an average price of 22 cents per share.

    Comment?

  17. Somewhat Favorable Media Coverage Somewhat Unlikely to Impact...Read the original story w/Photo

    Apr 24, 2018 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendations for Orexigen Therapeutics with our free daily email newsletter:

    Comment?

  18. Orexigen Therapeutics (OREX) Receives News Impact Rating of 0.07Read the original story w/Photo

    Apr 19, 2018 | IntersportsWire

    News articles about Orexigen Therapeutics have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time.

    Comment?

  19. Analysts See $-0.18 EPS for Affimed N.V. (AFMD); Orexigen Therapeutics (OREX) Shorts Lowered By 4.38%Read the original story w/Photo

    Apr 18, 2018 | Hill Country Times

    ... declined 25.96% since April 18, 2017 and is downtrending. It has underperformed by 37.51% the S&P500. Orexigen Therapeutics Inc (NASDAQ:OREX) had a decrease of 4.38% in short interest. OREX's SI was 709,300 shares in April as released by FINRA. Its ...

    Comment?

  20. Orexigen Therapeutics (OREX) Given News Sentiment Rating of -0.11Read the original story w/Photo

    Apr 4, 2018 | Daily Political

    Media headlines about Orexigen Therapeutics have been trending somewhat negative on Wednesday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time.

    Comment?